Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03521154 · FLOW

Participant flow

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    80mg once daily tablet
    id
    FG000
    title
    Osimertinib
  2. description
    Matching Placebo
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        111
      2. group Id
        FG001
        num Subjects
        52
      type
      Ongoing study at data cut-off
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        143
      2. group Id
        FG001
        num Subjects
        73
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        32
      2. group Id
        FG001
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        111
      2. group Id
        FG001
        num Subjects
        52
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Patients assigned to osimertinib may continue to receive osimertinib if, in the opinion of their treating physician, they are continuing to derive clinical benefit. Patients receiving placebo may receive open-label osimertinib, in accordance with local clinical practice and the judgement of their treating physician. For all patients, post-progression treatment with AZ-supply osimertinib may continue as long as the treating physician considers the patient to be deriving clinical benefit
Complete source fields
groups
  1. description
    80mg once daily tablet
    id
    FG000
    title
    Osimertinib
  2. description
    Matching Placebo
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        111
      2. group Id
        FG001
        num Subjects
        52
      type
      Ongoing study at data cut-off
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        143
      2. group Id
        FG001
        num Subjects
        73
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        32
      2. group Id
        FG001
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        111
      2. group Id
        FG001
        num Subjects
        52
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Patients assigned to osimertinib may continue to receive osimertinib if, in the opinion of their treating physician, they are continuing to derive clinical benefit. Patients receiving placebo may receive open-label osimertinib, in accordance with local clinical practice and the judgement of their treating physician. For all patients, post-progression treatment with AZ-supply osimertinib may continue as long as the treating physician considers the patient to be deriving clinical benefit

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice